{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:02:55Z","timestamp":1775149375912,"version":"3.50.1"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"27","license":[{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,5]]},"abstract":"<jats:p>Vedolizumab (VDZ), a monoclonal antibody to \u03b14\u03b27 integrin, is available for patients with moderate-to-severe ulcerative colitis (UC). This study planned to assess the real-world effectiveness and safety of VDZ for UC patients in Northern China. We enrolled patients with moderate-to-severe UC who underwent VDZ induction therapy from March 2021 to November 2022 at the Affiliated Hospital of Qingdao University. The primary outcome was clinical remission at weeks 14 and 52 after the initial VDZ therapy. Overall adverse events and risk factors associated with loss of response (LOR) were also evaluated. Seventy-three UC patients receiving VDZ therapy were included in this study. The rates of clinical response, clinical remission, and steroid-free clinical remission were 69.9%, 39.7%, and 34.2% at week 14 and 90.5%, 66.7%, and 64.4% at week 52, respectively. The mucosal remission rates were 37.5% (18\/48) at week 14\u2005\u00b1\u20058 and 27.3% (9\/33) at week 52\u2005\u00b1\u200516, while only 2 and 3 patients achieved mucosal healing at weeks 14\u2005\u00b1\u20058 and 52\u2005\u00b1\u200516, respectively. Of the UC patients, 23.3% experienced adverse events associated with VDZ, most of which were mild and self-limiting. Until the last follow-up, 37 of 73 UC patients experienced LOR during the maintenance period. Patients with a higher ulcerative colitis endoscopic severity index (UCEIS), partial Mayo scores (PMS), or hemoglobin below 120\u2009g\/L at baseline were more likely to experience LOR after VDZ induction therapy. VDZ is an effective and safe agent for patients with moderate-to-severe UC in Northern China. A high baseline UCEIS, PMS, or hemoglobin\u2005&lt;\u2005120\u2009g\/L may be an independent risk factor for LOR during the maintenance period.<\/jats:p>","DOI":"10.1097\/md.0000000000038759","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T16:06:23Z","timestamp":1720195583000},"page":"e38759","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Real-life effectiveness and safety of vedolizumab in moderate-to-severe ulcerative colitis: A single-center experience in Northern China"],"prefix":"10.1097","volume":"103","author":[{"given":"Jing","family":"Yan","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueli","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ailing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8428-0577","authenticated-orcid":false,"given":"Yonghong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260109","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/ibd\/izy327","article-title":"A state-of-the-art review of new and emerging therapies for the treatment of IBD.","volume":"25","author":"Chudy-Onwugaje","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"R2-20260109","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/ueg2.12350","article-title":"The epidemiology of inflammatory bowel disease in Asia and Asian immigrants to Western countries.","volume":"10","author":"Aniwan","year":"2022","journal-title":"United Eur Gastroenterol J"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5009\/gnl220017","article-title":"Acute severe ulcerative colitis: optimal strategies for drug therapy.","volume":"17","author":"Nakase","year":"2023","journal-title":"Gut liver"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis.","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.dld.2021.03.002","article-title":"Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: a narrative review.","volume":"53","author":"Armuzzi","year":"2021","journal-title":"Digestive Liver Dis"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"104455","DOI":"10.1016\/j.phrs.2019.104455","article-title":"Infliximab clinically treating ulcerative colitis: a systematic review and meta-analysis.","volume":"148","author":"Guo","year":"2019","journal-title":"Pharmacol Res"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of response to Anti-TNFs: definition, epidemiology, and management.","volume":"7","author":"Roda","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/ajg.2013.294","article-title":"Infectious and malignant complications of TNF inhibitor therapy in IBD.","volume":"108","author":"Targownik","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/14740338.2017.1300251","article-title":"The safety of vedolizumab for the treatment of ulcerative colitis.","volume":"16","author":"Novak","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"R10-20260109","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis.","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"R11-20260109","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/ecco-jcc\/jjx048","article-title":"Vedolizumab induces long-term mucosal healing in patients with Crohn\u2019s disease and ulcerative colitis.","volume":"11","author":"Noman","year":"2017","journal-title":"J Crohns Colitis"},{"key":"R12-20260109","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1586\/17474124.2016.1123618","article-title":"Vedolizumab for the treatment of ulcerative colitis.","volume":"10","author":"Stallmach","year":"2016","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R13-20260109","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41588-023-01384-0","article-title":"Genetic architecture of the inflammatory bowel diseases across East Asian and European ancestries.","volume":"55","author":"Liu","year":"2023","journal-title":"Nat Genet"},{"key":"R14-20260109","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1080\/00365521.2017.1304987","article-title":"Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the S wedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).","volume":"52","author":"Eriksson","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"R15-20260109","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/ecco-jcc\/jjz042","article-title":"Real-world effectiveness and safety of vedolizumab for the treatment of inflammatory bowel disease: the Scottish vedolizumab cohort.","volume":"13","author":"Plevris","year":"2019","journal-title":"J Crohns Colitis"},{"key":"R16-20260109","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/bcp.14235","article-title":"Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients.","volume":"86","author":"Bertani","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"R17-20260109","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1751-2980.2010.00421.x","article-title":"Progression of inflammatory bowel disease in China.","volume":"11","author":"Wang","year":"2010","journal-title":"J Dig Dis"},{"key":"R18-20260109","doi-asserted-by":"crossref","first-page":"1188751","DOI":"10.3389\/fphar.2023.1188751","article-title":"Effectiveness and safety of vedolizumab for ulcerative colitis: a single-center retrospective real-world study in China.","volume":"14","author":"Huang","year":"2023","journal-title":"Front Pharmacol"},{"key":"R19-20260109","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.","volume":"55","author":"Satsangi","year":"2006","journal-title":"Gut"},{"key":"R20-20260109","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1136\/gutjnl-2011-300486","article-title":"Developing an instrument to assess the endoscopic severity of ulcerative colitis: the ulcerative colitis endoscopic index of severity (UCEIS).","volume":"61","author":"Travis","year":"2012","journal-title":"Gut"},{"key":"R21-20260109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.crohns.2007.11.001","article-title":"European evidence-based Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis.","volume":"2","author":"Stange","year":"2008","journal-title":"J Crohns Colitis"},{"key":"R22-20260109","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s10620-021-06907-5","article-title":"Predictors of response to vedolizumab in patients with ulcerative colitis: results from the greek VEDO-IBD cohort.","volume":"67","author":"Bamias","year":"2022","journal-title":"Dig Dis Sci"},{"key":"R23-20260109","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1177\/2050640620951400","article-title":"Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study.","volume":"8","author":"Cohen","year":"2020","journal-title":"United Eur Gastroenterol J"},{"key":"R24-20260109","first-page":"170","article-title":"Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience.","volume":"33","author":"Ibraheim","year":"2020","journal-title":"Ann Gastroenterol"},{"key":"R25-20260109","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.3748\/wjg.v26.i30.4428","article-title":"Vedolizumab for ulcerative colitis: real world outcomes from a multicenter observational cohort of Australia and Oxford.","volume":"26","author":"Pulusu","year":"2020","journal-title":"World J Gastroenterol"},{"key":"R26-20260109","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/jgh3.12630","article-title":"Clinical response of vedolizumab at week 6 predicted endoscopic remission at week 24 in ulcerative colitis.","volume":"5","author":"Saito","year":"2021","journal-title":"JGH Open"},{"key":"R27-20260109","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820936536","article-title":"Good efficacy and safety of vedolizumab in Crohn\u2019s disease and ulcerative colitis in a real-world scenario.","volume":"13","author":"Zingone","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"key":"R28-20260109","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1093\/ibd\/izaa361","article-title":"Clinical outcomes and response predictors of vedolizumab induction treatment for Korean patients with inflammatory bowel diseases who failed anti-TNF therapy: a KASID prospective multicenter cohort study.","volume":"27","author":"Kim","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"R29-20260109","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.jfma.2021.11.012","article-title":"The effectiveness and safety of vedolizumab induction for moderate to severe ulcerative colitis for Asia patient: a real practice observational study.","volume":"121","author":"Kuo","year":"2021","journal-title":"J Formos Med Assoc"},{"key":"R30-20260109","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1093\/ibd\/izac269","article-title":"Real-world evidence of effectiveness and safety of vedolizumab for inflammatory bowel disease in Taiwan: a prospective nationwide registry (VIOLET) study.","volume":"29","author":"Lin","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"R31-20260109","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/apt.14919","article-title":"Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease.","volume":"48","author":"Kotze","year":"2018","journal-title":"Aliment Pharmacol Therap"},{"key":"R32-20260109","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/ecco-jcc\/jjz137","article-title":"The safety profile of vedolizumab in ulcerative colitis and Crohn\u2019s disease: 4 years of global post-marketing data.","volume":"14","author":"Cohen","year":"2020","journal-title":"J Crohns Colitis"},{"key":"R33-20260109","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/ajd.13754","article-title":"Nodular vasculitis during treatment with vedolizumab in a patient with ulcerative colitis.","volume":"63","author":"Abbenante","year":"2022","journal-title":"Australas J Dermatol"},{"key":"R34-20260109","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1093\/ibd\/izy153","article-title":"Low frequency of opportunistic infections in patients receiving vedolizumab in clinical trials and post-marketing setting.","volume":"24","author":"Ng","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"R35-20260109","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.3390\/biomedicines11061553","article-title":"Do vedolizumab trough levels predict the outcome of subsequent therapy in inflammatory bowel disease?","volume":"11","author":"Levartovsky","year":"2023","journal-title":"Biomedicines"},{"key":"R36-20260109","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1093\/ecco-jcc\/jjab067","article-title":"Dose optimisation for loss of response to vedolizumab- pharmacokinetics and immune mechanisms.","volume":"15","author":"Ungar","year":"2021","journal-title":"J Crohns Colitis"},{"key":"R37-20260109","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1093\/ibd\/izy171","article-title":"Predictors and management of loss of response to vedolizumab in inflammatory bowel disease.","volume":"24","author":"Shmidt","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"R38-20260109","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1159\/000509512","article-title":"Role of ulcerative colitis endoscopic index of severity (UCEIS) versus Mayo Endoscopic Subscore (MES) in predicting patients\u2019 response to biological therapy and the need for colectomy.","volume":"102","author":"Di Ruscio","year":"2021","journal-title":"Digestion"},{"key":"R39-20260109","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/ecco-jcc\/jjv210","article-title":"The ulcerative colitis endoscopic index of severity more accurately reflects clinical outcomes and long-term prognosis than the mayo endoscopic score.","volume":"10","author":"Ikeya","year":"2016","journal-title":"J Crohns Colitis"},{"key":"R40-20260109","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/ecco-jcc\/jju009","article-title":"European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases.","volume":"9","author":"Dignass","year":"2015","journal-title":"J Crohns Colitis"},{"key":"R41-20260109","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.3390\/jcm9072126","article-title":"Effect of vedolizumab on anemia of chronic disease in patients with inflammatory bowel diseases.","volume":"9","author":"Scarozza","year":"2020","journal-title":"J Clin Med"},{"key":"R42-20260109","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.crohns.2012.09.002","article-title":"Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management.","volume":"6","author":"Dignass","year":"2012","journal-title":"J Crohns Colitis"},{"key":"R43-20260109","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.3390\/biomedicines10092305","article-title":"Prognostic role of post-induction fecal calprotectin levels in patients with inflammatory bowel disease treated with biological therapies.","volume":"10","author":"Facciorusso","year":"2022","journal-title":"Biomedicines"},{"key":"R44-20260109","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/apt.14548","article-title":"Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study.","volume":"47","author":"Yacoub","year":"2018","journal-title":"Aliment Pharmacol Therap"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038759","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:02:49Z","timestamp":1767967369000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,5]]},"references-count":44,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000038759","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,5]]}}}